CellSource Future Growth

Future criteria checks 3/6

CellSource is forecast to grow earnings and revenue by 19.7% and 12.5% per annum respectively. EPS is expected to grow by 7.7% per annum. Return on equity is forecast to be 11.6% in 3 years.

Key information

19.7%

Earnings growth rate

7.7%

EPS growth rate

Life Sciences earnings growth	22.7%
Revenue growth rate	12.5%
Future return on equity	11.6%
Analyst coverage	Low
Last updated	30 Jun 2024

Recent future growth updates

Recent updates

A Look At The Fair Value Of CellSource Co., Ltd. (TSE:4880)

Aug 13

Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)

Jun 20

Earnings and Revenue Growth Forecasts

TSE:4880 - Analysts future estimates and past financials data (JPY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
10/31/2026	5,829	902	833	961	3
10/31/2025	5,133	676	609	768	3
10/31/2024	4,646	562	257	575	3
4/30/2024	4,567	812	266	914	N/A
1/31/2024	4,624	850	N/A	N/A	N/A
10/31/2023	4,510	923	487	846	N/A
7/31/2023	4,807	1,103	N/A	N/A	N/A
4/30/2023	4,746	1,119	1,198	1,248	N/A
1/31/2023	4,512	1,078	N/A	N/A	N/A
10/31/2022	4,273	1,017	748	847	N/A
7/31/2022	3,690	812	N/A	N/A	N/A
4/30/2022	3,276	691	542	641	N/A
1/31/2022	3,120	693	N/A	N/A	N/A
10/31/2021	2,922	651	837	898	N/A
7/31/2021	2,648	544	N/A	N/A	N/A
4/30/2021	2,312	424	474	518	N/A
1/31/2021	2,033	310	N/A	N/A	N/A
10/31/2020	1,855	274	298	330	N/A
7/31/2020	1,750	212	N/A	N/A	N/A
10/31/2019	1,611	199	142	195	N/A
10/31/2018	1,212	193	N/A	N/A	N/A
10/31/2017	519	111	N/A	N/A	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4880's forecast earnings growth (19.7% per year) is above the savings rate (0.3%).

Earnings vs Market: 4880's earnings (19.7% per year) are forecast to grow faster than the JP market (8.6% per year).

High Growth Earnings: 4880's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4880's revenue (12.5% per year) is forecast to grow faster than the JP market (4.3% per year).

High Growth Revenue: 4880's revenue (12.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 4880's Return on Equity is forecast to be low in 3 years time (11.6%).

CellSource Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Cellsource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023

CellSource Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2023

Recent updates

A Look At The Fair Value Of CellSource Co., Ltd. (TSE:4880)

Investor sentiment deteriorates as stock falls 21%

New major risk - Share price stability

Now 29% overvalued after recent price rise

Shaky Earnings May Not Tell The Whole Story For CellSource (TSE:4880)

Second quarter 2024 earnings released: EPS: JP¥7.58 (vs JP¥10.38 in 2Q 2023)

Now 22% undervalued after recent price drop

First quarter 2024 earnings released: EPS: JP¥7.23 (vs JP¥11.56 in 1Q 2023)

Investor sentiment improves as stock rises 16%

CellSource Co., Ltd. to Report Q2, 2024 Results on Jun 13, 2024

Less than half of directors are independent

Now 20% undervalued after recent price drop

CellSource Co., Ltd. to Report Q1, 2024 Results on Mar 11, 2024

Now 21% undervalued after recent price drop

Now 24% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 20%

Full year 2023 earnings released: EPS: JP¥48.88 (vs JP¥54.50 in FY 2022)

CellSource Co., Ltd., Annual General Meeting, Jan 25, 2024

CellSource Co., Ltd. to Report Fiscal Year 2023 Results on Dec 15, 2023

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: JP¥14.03 (vs JP¥15.05 in 3Q 2022)

New minor risk - Shareholder dilution

CellSource Co., Ltd. to Report Q3, 2023 Results on Sep 13, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: EPS: JP¥10.38 (vs JP¥8.20 in 2Q 2022)

Cellsource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023

First quarter 2023 earnings released: EPS: JP¥11.56 (vs JP¥8.32 in 1Q 2022)

Full year 2022 earnings released: EPS: JP¥54.50 (vs JP¥105 in FY 2021)

CellSource Co., Ltd. to Report Q1, 2023 Results on Mar 14, 2023

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: JP¥54.50 (vs JP¥105 in FY 2021)

CellSource Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2023

CellSource Co., Ltd., Annual General Meeting, Jan 27, 2023

Less than half of directors are independent

CellSource Co., Ltd. to Report Q4, 2022 Results on Dec 14, 2022

Third quarter 2022 earnings released: EPS: JP¥15.05 (vs JP¥25.88 in 3Q 2021)

Second quarter 2022 earnings released: EPS: JP¥8.20 (vs JP¥25.12 in 2Q 2021)

Less than half of directors are independent

CellSource Co., Ltd. to Report Q2, 2022 Results on Jun 13, 2022

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Now 23% undervalued after recent price drop

Now 21% undervalued after recent price drop

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: EPS JP¥25.12 (vs JP¥19.81 in 2Q 2020)

First quarter 2021 earnings released: EPS JP¥18.38 (vs JP¥36.57 in 1Q 2020)

CYBERDYNE Inc Forms Strategic Partnership with Cellsource Co., Ltd

Full year 2020 earnings released: EPS JP¥137 (vs JP¥137 in FY 2019)

CellSource Co., Ltd. to Report Q1, 2021 Results on Mar 15, 2021

CellSource Co., Ltd., Annual General Meeting, Jan 28, 2021

CellSource Co., Ltd. to Report Q3, 2020 Results on Sep 10, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies